Abstract: The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently selected from the group consisting of H, the following formula II: wherein —CH2— is optionally substituted by one or two substituents, the following formula III: wherein —CH2—C6H4— is optionally substituted by one or more substituents, and the following formula IV: wherein —CH2—CH2— is optionally substituted by one or more substituents, provided that a compound where all of R1 to R12 are H is excluded.

Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a disease characterized by fibrosis of a cell or a tissue, the pharmaceutical composition comprising a compound represented by formula 1 or a salt thereof, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently selected from the group consisting of H, the following formula II: wherein —CH2— is optionally substituted by one or two substituents, the following formula III: wherein —CH2—C6H4— is optionally substituted by one or more substituents, and the following formula IV: wherein —CH2—CH2— is optionally substituted by one or more substituents, provided that a compound where all of R1 to R12 are H is excluded.

Abstract: Provided are novel 2-fluorophenyl propionic acid derivatives which have excellent anti-inflammatory/analgesic effects while avoiding side effects such as gastrointestinal disorders, namely 2-fluorophenyl propionic acid derivatives represented by the formula (I) below or pharmaceutically acceptable salts thereof, [wherein, R1 represents a hydrogen atom, a halogen atom, or a substituted or unsubstituted phenyl group, X represents —CH2—, —NH—, —O—, or —S—, and Y specifically represents group (II) (wherein, Z1 represents —CO—, —CH(OH)—, or —CH2—, and n represents an integer of 1 or 2.

Abstract: Provided are novel 2-fluorophenyl propionic acid derivatives which have excellent anti-inflammatory/analgesic effects while avoiding side effects such as gastrointestinal disorders, namely 2-fluorophenyl propionic acid derivatives represented by the formula (I) below or pharmaceutically acceptable salts thereof, [wherein, R1 represents a hydrogen atom, a halogen atom, or a substituted or unsubstituted phenyl group, X represents —CH2—, —NH—, —O—, or —S—, and Y specifically represents group (II) (wherein, Z1 represents —CO—, —CH(OH)—, or —CH2—, and n represents an integer of 1 or 2.

Abstract: The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R1, R2, R2?, R3, R4, X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.

Abstract: A probe is utilized in the hybridization with a natural nucleic acid to form a double strand. The probe contains a cytosine derivative which specifically binds to guanine by forming two hydrogen bonds with the guanine nucleotide and/or a guanine derivative which specifically binds to cytosine by forming two hydrogen bonds with the cytosine nucleotide. This enables a large number of hybridization reactions to be carried out at once under uniform conditions.

Abstract: A method of specifically cleaving a double-stranded DNA (a target nucleic acid) at a specific nucleic acid sequence, which comprises irradiating a solution containing at least the target nucleic acid, a nucleic acid probe (a single-stranded oligonucleotide) linked to an intercalater and spermine with light with an absorption wavelength of the intercalater.

Abstract: A labeled nucleic acid probe comprising a single-stranded oligonucleotide probe having a nucleic acid sequence complementary to a specific nucleic acid sequence in a target nucleic acid and an intercalating fluorochrome bound to said probe is used to detect the target nucleic acid by a convenient, single-stage method in a homogeneous system. The formation of a complementary bond between the probe and the target nucleic acid can be detected and the amount of the resulting complementary binding product determined without requiring any extra step such as for removing the excess probe which has not participated in the complementary binding.